TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES

Saved in:
Bibliographic Details
Published in:Hematological oncology 2021-06, Vol.39 (S2)
Main Authors: Cheah, C. Y, Jurczak, W, Lasica, M, Wickham, N, Wróbel, T, Walewski, J, Yannakou, C. K, Cheung, S, Lewis, K. L, Długosz‐Danecka, M, Giannopoulos, K, Miskin, H. P, Tang, J.‐P, Normant, E, O'Connor, O. A, Ricart, A. D, Tam, C. S
Format: Article
Language:English
Subjects:
Bruton's tyrosine kinase
Enzyme inhibitors
Kinases
Monoclonal antibodies
Protein-tyrosine kinase
Tyrosine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.148_2880